American Academy of Ophthalmology (AAO) 2023
Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months: Results From 12 Months of the GALE Open-Label Extension Study_Jeffrey Heier
Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months: Results From 12 Months of the GALE Open-Label Extension Study_Charles C. Wykoff, et al.
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of Three Phase 3 Trials
Artificial Intelligence (AI) in the Management of Geographic Atrophy (GA)
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.